LLY
Eli Lilly and Company
LLY has the edge over LMAT overall, supported by stronger fundamentals and stronger modeled upside.
LMAT
LeMaitre Vascular, Inc.
LMAT has slightly lower modeled downside risk, despite its lower overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LMAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
LMAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LMAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $77.65 | — |
| Current | 28x | $77.65 | — |
| Cheap | 35x | $97.74 | +26% |
| Fair | 43x | $118 | +52% |
| Expensive | 52x | $143 | +85% |
Historical ranges are pointers, not guarantees.
LMAT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LMAT on the outlook, with more favorable profitability expectations.
LMAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LMAT, with profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LMAT on earnings, with stronger typical year-over-year growth.
LMAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.08 | +12% |
| Q3 2026 | $2.76 | +19% |
| Q2 2026 | $2.86 | +40% |
| Q1 2026 | $2.72 | +38% |
| Q4 2025 | $2.52 | +31% |
| Q3 2025 | $2.31 | +26% |
| Q2 2025 | $2.05 | +23% |
| Q1 2025 | $1.97 | +30% |
| Q4 2024 | $1.93 | +44% |
LMAT's earnings per share have climbed steadily: $2.76 over the past year, up 19% from the year before, and higher year over year for 14 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LMAT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LMAT on profitability, with a higher operating margin.
LMAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68M | +11% |
| Q2 2026 | $70.4M | +9.6% |
| Q1 2026 | $66.6M | +11% |
| Q4 2025 | $64.5M | +16% |
| Q3 2025 | $61M | +11% |
| Q2 2025 | $64.2M | +15% |
| Q1 2025 | $59.9M | +12% |
| Q4 2024 | $55.7M | +14% |
LMAT's revenue has grown year over year every quarter since late 2020: $68M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -7.2 points |
| Q2 2026 | 29% | +3.9 points |
| Q1 2026 | 27% | +5.6 points |
| Q4 2025 | 29% | +6.1 points |
| Q3 2025 | 33% | +9.3 points |
| Q2 2025 | 25% | -0.6 points |
| Q1 2025 | 21% | -1.1 points |
| Q4 2024 | 23% | +2.2 points |
LMAT's operating margin was 26% last quarter, down 7.2 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
LMAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $19.7M | -26% |
| Q2 2026 | $13.7M | -28% |
| Q1 2026 | $12.3M | +61% |
| Q4 2025 | $21.4M | +63% |
| Q3 2025 | $26.5M | +111% |
| Q2 2025 | $18.9M | +145% |
| Q1 2025 | $7.7M | +107% |
| Q4 2024 | $13.1M | +39% |
LMAT's free cash flow has been positive every quarter for seven years: $67M over the past year, up 1.2% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LMAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6% | -1.5M shares |
| 1 year | -5.4% | -1.3M shares |
| 3 years | +2.6% | +590K shares |
| 5 years | +5.2% | +1.1M shares |
| Available history | +14% | +2.7M shares |
LMAT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $17,000 |
| Q1 2026 | $460,000 |
| Q4 2025 | $1.2M |
| Q3 2025 | — |
| Q2 2025 | $4,000 |
| Q1 2025 | $601,000 |
| Q4 2024 | $1.4M |
LMAT has spent almost nothing on buybacks in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LMAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
LMAT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LMAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 7.0 | Oversold |
LMAT's weekly RSI is 37 (neutral) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LMAT PE vs Healthcare Sector
| Metric | LMAT | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 8.8% above |
| PE % | 3 | 29 | 26 pts below |
LMAT has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LMAT on trend strength, trading above more of its moving averages.
LMAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 3.8% below |
| 20 week MA | $85.8 | 9.5% below |
| 50 week MA | $92.4 | 16% below |
| 100 week MA | $90.2 | 14% below |
| 200 week MA | $79.0 | 1.7% below |
LMAT is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LMAT on returns for 2026, with the stronger performance.
LMAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.2 | $38.4 | +6.1% |
| 2021 | $38.4 | $51.5 | +34% |
| 2022 | $51.5 | $45.8 | -11% |
| 2023 | $45.8 | $56.8 | +24% |
| 2024 | $56.8 | $92.8 | +64% |
| 2025 | $92.8 | $83.8 | -9.8% |
| 2026 YTD | $83.8 | $77.7 | -7.3% |
LMAT has finished higher in four of the last six years. It's down 7.3% so far in 2026.